Despite online claims, President Donald Trump’s executive orders did not include removing Medicare’s $35 monthly out-of-pocket price cap, which is set by law.

Despite online claims, President Donald Trump’s executive orders did not include removing Medicare’s $35 monthly out-of-pocket price cap, which is set by law.

Trump dismissed the order as part of what he called Biden’s “unpopular, inflationary, illegal, and radical practices.”

The majority of Americans think prescription drug costs are unreasonable and believe a major contributor to the high cost is profits made by pharmaceutical companies, a survey by KFF found.

The Democratic National Committee ( DNC) is going on the offense against President Donald Trump just two days into his second term, blasting the 45th and 47th President over what they say is a plan to follow through on the controversial Project 2025 agenda, including by cutting Social Security, Medicare and Medicaid.

The president reinstated a policy blocking U.S. aid to foreign organizations that use funds for abortion. He also overturned two Biden executive orders, contending they violated the law barring federal funding for abortion.

On the first day of his second term, President Donald Trump signed an executive ... As of Jan. 23, 2025, Trump has not gotten rid of Medicare’s $35 cap on insulin prices, nor has he changed ...

As the next round of Medicare drug pricing negotiations get underway, experts predict President Trump may seek to weaken the program.

President Trump is rolling back Biden healthcare policies, such as expansions to the Affordable Care Act – a move Democrats described as an "attack" on the federal program.

The list includes Baker’s longtime political adviser Jim Conroy, former Baker campaign manager Brian Wynne and David Drummond, a Scott Brown alum who also served as finance director for Baker’s political committee, according to a person familiar with Kennealy’s operation.

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation and patient access to treatments.